Allergy Therapeutics(DE:HHU)
€0.030.00 (-15.38%)
DE:HHU
Allergy Therapeutics financials statements
€0.03
At close:0.00 (-15.38%)
Allergy Therapeutics (HHU) Ratios
1 Followers
Allergy Therapeutics Ratios
DE:HHU's free cash flow for Q4 2026 was £-22.55M. For the 2026 fiscal year, DE:HHU's free cash flow was decreased by £-2.12M and operating cash flow was £-20.43M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.29 | 1.28 | 1.63 | 1.81 | 2.35 |
| Quick Ratio | 1.61 | 0.76 | 1.01 | 1.18 | 1.72 |
| Cash Ratio | 1.05 | 0.47 | 0.63 | 0.80 | 1.14 |
| Solvency Ratio | -0.48 | -0.38 | -0.59 | -0.60 | -0.27 |
| Operating Cash Flow Ratio | -1.39 | -1.06 | -1.56 | -1.67 | -0.78 |
| Short-Term Operating Cash Flow Coverage | -12.31 | -70.91 | -53.56 | -47.71 | -14.82 |
| Net Current Asset Value | £ -44.68M | £ -61.06M | £ -27.64M | £ -31.18M | £ 7.21M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.77 | 0.89 | 0.48 | 0.54 | 0.14 |
| Debt-to-Equity Ratio | -6.46 | -2.13 | 8.35 | 17.42 | 0.28 |
| Debt-to-Capital Ratio | 1.18 | 1.88 | 0.89 | 0.95 | 0.22 |
| Long-Term Debt-to-Capital Ratio | 1.21 | 2.13 | 0.86 | 0.93 | 0.04 |
| Financial Leverage Ratio | -8.41 | -2.40 | 17.48 | 32.32 | 1.93 |
| Debt Service Coverage Ratio | -3.29 | -4.02 | -7.10 | -12.15 | -6.57 |
| Interest Coverage Ratio | -5.02 | -4.31 | -9.09 | -14.28 | -24.03 |
| Debt to Market Cap | 0.15 | 0.14 | 0.13 | 3.85 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.06 | 0.02 |
| Net Debt to EBITDA | -1.18 | -1.61 | -0.59 | -0.58 | 1.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.39% | 45.65% | 53.87% | 54.86% | 67.27% |
| EBIT Margin | -68.45% | -61.04% | -63.51% | -67.91% | -17.67% |
| EBITDA Margin | -60.70% | -53.46% | -55.69% | -60.82% | -11.94% |
| Operating Profit Margin | -68.45% | -53.60% | -63.87% | -58.49% | -17.87% |
| Pretax Profit Margin | -87.55% | -73.48% | -70.95% | -71.53% | -18.41% |
| Net Profit Margin | -86.04% | -72.91% | -72.86% | -72.28% | -18.93% |
| Continuous Operations Profit Margin | -86.04% | -72.91% | -72.86% | -72.28% | -18.93% |
| Net Income Per EBT | 98.28% | 99.23% | 102.68% | 101.05% | 102.83% |
| EBT Per EBIT | 127.91% | 137.08% | 111.09% | 122.30% | 103.05% |
| Return on Assets (ROA) | -59.08% | -59.42% | -62.04% | -64.51% | -18.88% |
| Return on Equity (ROE) | 496.92% | 142.35% | -1084.28% | -2084.75% | -36.48% |
| Return on Capital Employed (ROCE) | -63.92% | -73.12% | -79.62% | -72.30% | -23.68% |
| Return on Invested Capital (ROIC) | -60.36% | -69.33% | -75.99% | -69.69% | -22.74% |
| Return on Tangible Assets | -61.76% | -63.41% | -66.87% | -72.97% | -21.34% |
| Earnings Yield | -12.62% | -10.59% | -22.86% | -612.38% | -0.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.61 | 6.90 | 7.06 | 8.41 | 6.95 |
| Payables Turnover | 4.55 | 6.66 | 6.34 | 6.58 | 5.56 |
| Inventory Turnover | 2.24 | 2.15 | 2.00 | 2.32 | 2.09 |
| Fixed Asset Turnover | 2.26 | 2.27 | 2.32 | 2.56 | 3.60 |
| Asset Turnover | 0.69 | 0.81 | 0.85 | 0.89 | 1.00 |
| Working Capital Turnover Ratio | 3.21 | 5.39 | 3.96 | 3.03 | 2.28 |
| Cash Conversion Cycle | 162.06 | 167.85 | 176.86 | 145.24 | 161.76 |
| Days of Sales Outstanding | 79.16 | 52.86 | 51.73 | 43.42 | 52.51 |
| Days of Inventory Outstanding | 163.15 | 169.79 | 182.69 | 157.33 | 174.88 |
| Days of Payables Outstanding | 80.26 | 54.80 | 57.56 | 55.50 | 65.63 |
| Operating Cycle | 242.31 | 222.65 | 234.42 | 200.74 | 227.39 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.05 | -0.02 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.05 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | -6.52 | -8.80 | -9.45 | -6.62 | -4.62 |
| Capital Expenditure Coverage Ratio | -6.52 | -8.80 | -9.45 | -6.62 | -4.62 |
| Operating Cash Flow Coverage Ratio | -0.48 | -0.48 | -1.04 | -0.86 | -1.34 |
| Operating Cash Flow to Sales Ratio | -0.54 | -0.52 | -0.58 | -0.52 | -0.19 |
| Free Cash Flow Yield | -9.08% | -8.44% | -20.20% | -505.95% | -0.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.89 | -9.46 | -4.37 | -0.16 | -968.54 |
| Price-to-Sales (P/S) Ratio | 6.82 | 6.88 | 3.19 | 0.12 | 183.36 |
| Price-to-Book (P/B) Ratio | -39.36 | -13.44 | 47.44 | 3.40 | 353.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.01 | -11.85 | -4.95 | -0.20 | -777.22 |
| Price-to-Operating Cash Flow Ratio | -12.70 | -13.20 | -5.47 | -0.23 | -945.55 |
| Price-to-Earnings Growth (PEG) Ratio | -1.10 | 0.44 | 0.05 | -0.00 | 1.68 |
| Enterprise Value Multiple | -12.41 | -14.48 | -6.31 | -0.78 | -1534.25 |
| Enterprise Value | 450.81M | 426.23M | 194.01M | 28.18M | 13.33B |
| EV to EBITDA | -12.41 | -14.48 | -6.31 | -0.78 | -1534.25 |
| EV to Sales | 7.53 | 7.74 | 3.51 | 0.47 | 183.22 |
| EV to Free Cash Flow | -12.16 | -13.33 | -5.46 | -0.79 | -776.64 |
| EV to Operating Cash Flow | -14.03 | -14.84 | -6.04 | -0.91 | -944.84 |
| Tangible Book Value Per Share | -0.00 | -0.01 | -0.00 | -0.01 | 0.05 |
| Shareholders’ Equity Per Share | -0.00 | -0.01 | 0.00 | 0.00 | 0.06 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | 0.01 | -0.03 | -0.03 | -0.08 |
| Revenue Per Share | 0.01 | 0.01 | 0.01 | 0.09 | 0.11 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | -0.06 | -0.02 |
| Tax Burden | 0.98 | 0.99 | 1.03 | 1.01 | 1.03 |
| Interest Burden | 1.28 | 1.20 | 1.12 | 1.05 | 1.04 |
| Research & Development to Revenue | 0.32 | 0.28 | 0.41 | 0.34 | 0.22 |
| SG&A to Revenue | 0.78 | 0.70 | 0.41 | 0.42 | 0.29 |
| Stock-Based Compensation to Revenue | 0.00 | 0.02 | 0.00 | 0.00 | 0.01 |
| Income Quality | 0.62 | 0.73 | 0.80 | 0.72 | 1.02 |
Currency in GBP

